Demographics, underlying malignancies, and medications
Forty patients with biopsy-proven cutaneous irAEs (24 males, 18 females)
met the eligibility criteria. Patient demographics, underlying
malignancies, and the ICIs administered are summarized in Table 1. The
most frequent cancer types were lung cancer (n = 17) and melanoma (n =
12). Other malignancies (n = 13) included Merkel cell carcinoma (n = 1),
cutaneous squamous cell carcinoma of the head and neck (n = 3),
sebaceous carcinoma of the head and neck (n = 1), esophageal squamous
cell carcinoma (n = 2), gastric adenocarcinoma (n = 1), renal cell
carcinoma (n = 4), and urothelial carcinoma (n = 1).
Cutaneous irAEs were most commonly associated with the anti–PD-1
antibodies nivolumab (19/42, 45.2%) and pembrolizumab (10/42, 23.8%),
followed by combination anti–PD-1 and anti–CTLA-4 therapy with
nivolumab and ipilimumab (5/42, 11.9%). The anti–PD-L1 antibodies
atezolizumab (4/42, 9.5%) and avelumab (2/42, 4.8%) and anti–CTLA-4
antibody ipilimumab (2/42, 4.8%) were associated with fewer cutaneous
irAEs.